启迪药业集团股份公司 内幕信息知情人登记管理制度 （公司第十届董事会第二次会议审议通过） 1、总 则 1.1 为进一步规范启迪药业集团股份公司（以下简称"公司"）的内幕信息管理， 加强内幕信息保密工作，建立内幕信息知情人档案材料，以维护信息披露公平、公正原 则，保护投资者的合法权益，有效防范内幕交易等证券违法违规行为，根据《中华人民 共和国公司法》《中华人民共和国证券法》《上市公司信息披露管理办法》《深圳证券 交易所股票上市规则》《上市公司监管指引第5号——上市公司内幕信息知情人登记管理 制度》等有关法律、法规和《公司章程》《公司信息披露管理制度》的相关规定，制定 本制度。 1.2 本制度适用于公司各部门、控股子公司及公司能够对其实施重大影响的参股公 司。 2、内幕信息的含义与范围 2.1 本制度所指内幕信息，根据《证券法》相关规定，涉及公司的经营、财务或者 对公司股票交易价格有重大影响的尚未公开的信息。 尚未公开是指公司尚未在中国证券监督管理委员会（以下简称"中国证监会"）及 证券交易所指定的上市公司信息披露媒体公开披露的信息。 2.2 本制度所指内幕信息的范围包括但不限于： 2.2.1 公司的经营方针和经 ...

证券代码：000590 证券简称：启迪药业 公告编号：2023-043 启迪药业集团股份公司 关于募集资金专户完成销户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证监会《关于核准启迪古汉集团股份有限公司非公开发行股票的批 复》（证监许可[2017]87 号）文件的核准，公司获准非公开发行不超过 1,614 万股新股。本次实际发行人民币普通股（A 股）16,140,000 股，发行价格为人民 币 17.76 元/股，募集资金总额为人民币 286,646,400.00 元，扣除发行费用后的 募集资金净额为人民币 278,696,400.00 元。 公司已按照《中华人民共和国公司法》、《中华人民共和国证券法》、《上 市公司证券发行管理办法》、《深圳证券交易所股票上市规则》、《上市公司监 管指引第2号-上市公司募集资金管理和使用的监管要求》等相关规定的要求制定 并修订了《公司募集资金管理办法》（以下简称"《管理办法》"），对募集资 金实行专户存储制度，对募集资金的存放、使用、项目实施管理、投资项目的变 更及使用情况的监督等进行了 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥101,199,883.45, representing a 10.76% increase compared to ¥91,371,093.42 in the same period last year[5] - Net profit attributable to shareholders decreased by 47.33% to ¥6,584,800.39 from ¥12,501,913.58 year-on-year[5] - Basic and diluted earnings per share both fell by 47.32% to ¥0.0275 from ¥0.0522 in the same period last year[5] - In Q1 2023, the company's net profit was CNY 6,608,510.61, a decrease of 46.9% compared to CNY 12,450,763.04 in Q1 2022[18] - Operating profit for Q1 2023 was CNY 8,275,180.58, down 44.1% from CNY 14,824,181.88 in the same period last year[18] - Total revenue from operating activities was CNY 71,177,372.95, a decline of 8.8% compared to CNY 78,919,381.36 in Q1 2022[19] Cash Flow - The net cash flow from operating activities was -¥71,412,078.80, a decline of 87.61% compared to -¥38,063,764.03 in the previous year[5] - The company reported a net cash outflow from operating activities of CNY -71,412,078.80, worsening from CNY -38,063,764.03 in the previous year[19] - Cash and cash equivalents at the end of Q1 2023 stood at CNY 181,835,488.02, compared to CNY 119,572,132.68 at the end of Q1 2022[20] - The company's cash flow from financing activities increased significantly by 1312.92% to ¥18,670,529.41, primarily due to new bank loans[9] - The company’s financing activities generated a net cash inflow of CNY 18,670,529.41, compared to CNY 1,321,413.90 in the same period last year[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,160,864,614.18, a decrease of 0.50% from ¥1,166,753,854.92 at the end of the previous year[5] - Total assets as of March 31, 2023, were ¥1,160,864,614.18, down from ¥1,166,753,854.92 at the beginning of the year, a decrease of 0.5%[16] - Total liabilities decreased to ¥451,762,232.36 from ¥464,259,983.71, a decline of 2.7%[16] - The company's equity attributable to shareholders increased by 0.94% to ¥705,053,220.37 from ¥698,468,419.98 at the end of the previous year[5] Expenses - Total operating costs for Q1 2023 were ¥94,851,970.71, up 21.2% from ¥78,324,425.75 in Q1 2022[17] - The company recorded a net loss from operating activities, with a significant increase in expenses leading to a net profit decline of 46.92%[9] - Research and development expenses increased to CNY 3,035,083.94, up from CNY 2,678,282.04 in the previous year, reflecting a focus on innovation[18] - The company recorded a significant decrease in sales expenses, which rose to CNY 22,923,928.51 from CNY 15,070,557.79, indicating increased investment in marketing[18] - The company's financial expenses included interest expenses of CNY 1,051,034.62, compared to CNY 96,635.60 in the previous year, highlighting increased borrowing costs[18] Receivables and Inventory - The company's receivables financing increased by 60.89% to ¥86,750,573.95, mainly due to an increase in received bills[8] - The company reported a significant increase in accounts receivable financing to ¥86,750,573.95 from ¥53,920,546.58, an increase of 60.9%[15] - Accounts receivable decreased to ¥18,867,109.01 from ¥24,369,559.97, a reduction of 22.6%[15] - Inventory increased to ¥133,364,483.70 from ¥118,222,841.95, reflecting a growth of 12.8%[15] Shareholder Information - The number of major shareholders includes启迪科技服务有限公司 with 70,432,904 shares, representing a significant portion of the company's equity[12]

股票代码：000590 股票简称：启迪药业 启迪药业集团股份公司投资者关系活动记录表 编号：2023-001 投资者关系活动类 别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及人 员姓名 线上参与启迪药业 2022 年度网上业绩说明会的投资者 时间 2023 年 04 月 14 日（星期五）下午 15:00-17:00 地点 "启迪药业投资者关系"微信小程序 上市公司接待人员 姓名 董事、总裁：冯雪先生 董事、副总裁、财务总监：唐婷女士 副总裁、董事会秘书：曹定兴先生 独立董事：龙小明先生 投资者关系活动主 要内容介绍 1、问：请问一下股票价格为什么不高？ 答：尊敬的投资者您好，二级市场的股价表现是多种因 素综合作用的结果。公司将继续努力推动公司高质量发 展，聚焦行业发展，通过创新驱动，品牌驱动，资本驱 动做大做强公司业绩与市值规模，为消费市场提供品质 过硬的品牌产品，为资本市场创造更有投资价值的上市 公司。感谢您对公司的关心和关注。 2、问：古汉养生精在改善老年痴呆等老年退行性疾病 等方面的研究进程？ 答：尊 ...

证券代码：000590 证券简称：启迪药业 公告编号：2023-018 参与方式一：在微信小程序中搜索"启迪药业投资者关系"； 参与方式二：微信扫一扫以下二维码： 投资者依据提示，授权登入"启迪药业投资者关系"小程序，即可参与交流。 出席本次网上说明会的人员有：公司董事、总裁冯雪先生，公司副总裁、董 事会秘书曹定兴先生，公司董事、副总裁、财务总监唐婷女士，公司独立董事龙 小明先生。敬请广大投资者积极参与。 启迪药业集团股份公司 关于举行2022年度网上业绩说明会的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，公告不存在虚假 记载、误导性陈述或者重大遗漏。 启迪药业集团股份公司（以下简称"公司"）已于2023年3月28日在巨潮资讯 网（http://www.cninfo.com.cn/）上披露了《启迪药业2022年年度报告》。 为便于广大投资者进一步了解公司2022年年度经营情况，公司定于2023年4 月14日（星期五）上午15:00至17:00时在"启迪药业投资者关系"小程序举行2022 年度网上业绩说明会。本次网上业绩说明会将采用网络远程的方式举行，投资者 可登陆"启迪药业投资者关系"小程序参与 ...

Financial Performance - The company's operating revenue for 2022 was ¥350,528,110.13, representing a 16.54% increase compared to ¥300,774,612.76 in 2021[23] - The net profit attributable to shareholders decreased by 48.80% to ¥18,145,855.14 from ¥35,438,603.68 in the previous year[23] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥11,599,403.81, down 48.10% from ¥22,350,567.85 in 2021[23] - Basic earnings per share decreased by 48.78% to ¥0.0758 from ¥0.1480 in the previous year[23] - The net profit attributable to shareholders for 2022 was approximately ¥698.47 million, representing a 2.67% increase from ¥680.32 million in 2021[24] - The company reported a total revenue of ¥113.98 million in Q4 2022, with a total annual revenue of ¥350.53 million for the year[27] - The net profit attributable to shareholders in Q1 2022 was ¥12.50 million, while Q2 saw a loss of ¥0.95 million, indicating volatility in quarterly performance[27] Cash Flow and Assets - The net cash flow from operating activities increased significantly by 116.20% to ¥54,473,687.13 from ¥25,196,296.92 in 2021[23] - Total assets at the end of 2022 were ¥1,166,753,854.92, a 20.55% increase from ¥967,825,750.64 at the end of 2021[23] - The company achieved operating cash inflow increased by 67.16% to ¥603,348,143.78, driven by higher cash receipts from sales[62] - The net cash flow from operating activities surged by 116.20% to ¥54,473,687.13, indicating improved operational efficiency[62] - As of the end of 2022, cash and cash equivalents amounted to ¥235,421,368.70, representing 20.18% of total assets, a decrease of 5.72% from the beginning of the year[65] Investments and Acquisitions - The company acquired 90% of Qidi Bio for ¥23.5 million to enhance its health product trading business[46] - In August 2022, the company completed the acquisition of 100% of Guangdong Xiantong Pharmaceutical for ¥22 million, aimed at expanding its product line and market competitiveness[46] - The company completed the approval process for two classic formulas, enhancing its product portfolio and market competitiveness[61] - The company has committed to a total investment of 1,000 million yuan for the annual production of 400 million bottles of Gu Han Yang Sheng oral liquid, with 99.99% of the investment completed as of the report date[81] Revenue Sources and Product Performance - The pharmaceutical manufacturing sector accounted for ¥346,525,339.20, or 98.86% of total revenue, with a year-on-year growth of 16.09%[51] - The revenue from traditional Chinese medicine products was ¥295,016,014.20, which is 84.16% of total revenue, showing a growth of 3.56% compared to the previous year[51] - The revenue from direct supply and controlled sales increased by 124.04% year-on-year, reaching ¥74,666,933.4[53] - The company reported a 4.30% increase in revenue for its traditional Chinese medicine subsidiary, but net profit decreased by 34.58% due to rising costs[89] Marketing and Expansion Strategies - The company is enhancing its digital transformation and integrating technology with business operations to drive innovation[44] - The company is focusing on optimizing its marketing structure and expanding its e-commerce presence through platforms like Youzan Mall, Tmall, and JD.com[48] - The company will focus on its core business and expand its market presence nationwide, leveraging the acquisition of Guangdong Xiantong to enhance its terminal sales network and accelerate market expansion[90] - The company plans to strengthen its marketing system and brand management, focusing on key products like "Guhang Yangshengjing" and "Yixin Shupian" to transition from a regional to a national brand[92] Risk Management and Governance - The management has outlined potential risks and countermeasures in the report, emphasizing the importance of investor awareness regarding investment risks[4] - The company is addressing potential goodwill impairment risks from the acquisition of Guangdong Xiantong by enhancing management and operational efficiency[95] - The company has established a robust governance structure, complying with relevant laws and regulations[98] - The company has not reported any significant differences in governance practices compared to regulatory requirements[98] Employee and Management Structure - The total number of employees at the end of the reporting period is 1,309, with 76 in the parent company and 1,233 in major subsidiaries[129] - The professional composition includes 323 production personnel, 191 sales personnel, 72 technical personnel, 32 financial personnel, 214 administrative personnel, and 477 others[130] - The company has implemented a restricted stock incentive plan for 2022, reflecting its commitment to employee motivation and retention[127] - The current management team includes experienced professionals with diverse backgrounds in finance, law, and pharmaceuticals[111][112][113] Environmental and Social Responsibility - The company operates a wastewater treatment system with a capacity of 1000m³/d, achieving a removal efficiency of 98% for pollutants[146] - The company has implemented a comprehensive quality assurance system for environmental monitoring, adhering to national standards[151] - In 2022, the company invested CNY 30,000 in rural revitalization efforts, establishing sales channels for local specialty agricultural products[155] - The company donated medical supplies valued at over CNY 360,000 to frontline healthcare workers and disease control departments[155] Shareholder and Financial Management - The total pre-tax remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 3.7259 million[118] - The company’s total remuneration for the board and management reflects a commitment to competitive compensation practices[117] - The company has not proposed any cash dividend distribution plan for the reporting period despite having a positive profit available for distribution to shareholders[133] - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[163]

启迪药业集团股份公司 2022 年第三季度报告 启迪药业集团股份公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 证券代码：000590 证券简称：启迪药业 公告编号：2022-043 启迪药业集团股份公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 193,430,018.28 | 184.89% | 371,82 ...

证券代码：000590 证券简称：启迪药业 公告编号：2022-041 启迪药业集团股份公司 关于参加湖南辖区上市公司2022年投资者网上集体 接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为贯彻落实《国务院办公厅关于进一步加强资本市场中小投资者合法权益保 护工作的意见》文件精神，进一步做好公司投资者关系管理工作，增强与广大投 资者的沟通交流，切实提高公司透明度和治理水平，启迪药业集团股份公司（以 下简称"公司"）将参加由湖南证监局、湖南省上市公司协会与深圳市全景网络 有限公司联合举办的"湖南辖区上市公司 2022年投资者网上集体接待日"活动， 现将有关事项公告如下： 本次投资者网上接待日活动将通过深圳市全景网络有限公司提供的互联网 平台，采用网络远程方式举行，投资者可以登录"全景·路演天下"网站 (http://rs.p5w.net)参与本次投资者网上集体接待日活动，活动时间为：2022 年9月29日（星期四）15:30至 16:55。 届时公司董事会秘书、证券事务代表将通过网络在线问答互动的形式与投资 者进行沟通和交流，欢迎广大投资者积 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥178,391,627.39, representing a 20.12% increase compared to ¥148,513,172.63 in the same period last year[17]. - The net profit attributable to shareholders of the listed company decreased by 60.43% to ¥11,554,184.55 from ¥29,199,524.56 year-on-year[17]. - The net profit after deducting non-recurring gains and losses was ¥4,995,227.47, down 78.75% from ¥23,506,965.08 in the previous year[17]. - Basic earnings per share decreased by 60.46% to ¥0.0482 from ¥0.1219 year-on-year[17]. - The company's net profit for the first half of 2022 was ¥11,582,235.79, a decrease of 60.3% compared to ¥29,199,524.56 in the same period of 2021[132]. - The company reported a significant increase in cash and cash equivalents, with a net increase of ¥69,704,048.45, a 159.82% rise compared to the previous year[36]. - The total comprehensive income for the first half of 2022 was ¥11,582,235.79, a significant decrease from ¥29,199,524.56 in the first half of 2021[132]. Cash Flow - The net cash flow from operating activities increased by 40.17% to ¥44,160,594.59, compared to ¥31,504,708.13 in the same period last year[17]. - Cash inflows from operating activities for the first half of 2022 were ¥256,559,891.87, an increase of 34.4% from ¥190,884,978.29 in the first half of 2021[136]. - The net cash flow from investment activities was ¥24,400,626.06, a recovery from a negative cash flow of ¥142,956,896.48 in the previous period[137]. - The total cash flow from financing activities showed a net increase of ¥1,142,827.80, compared to a net outflow of ¥5,062,777.78 in the prior year[137]. - The ending balance of cash and cash equivalents rose to ¥316,065,329.07 from ¥226,437,922.84, reflecting a year-over-year increase of approximately 39.5%[137]. Assets and Liabilities - Total assets at the end of the reporting period were ¥963,489,268.09, a slight decrease of 0.45% from ¥967,825,750.64 at the end of the previous year[17]. - The total liabilities as of June 30, 2022, amounted to CNY 268,085,696.83, down from CNY 285,504,415.17 at the beginning of the year, a decrease of 6.67%[128]. - The company's total equity as of June 30, 2022, was CNY 695,403,571.26, up from CNY 682,321,335.47 at the beginning of the year, an increase of 1.59%[128]. - The total liabilities included accounts payable of ¥29,628,277.33, a decrease from ¥31,544,286.40[123]. Investment and Development - The company has outlined potential risks and countermeasures in its management discussion section, which investors should pay attention to[3]. - The company is focusing on market expansion, channel control, and brand building as part of its marketing strategy to explore new growth opportunities[28]. - The company has completed the registration review for the health food product Dan Shen Hong Hua oral liquid, with the registration certificate expected to be issued soon[31]. - The company has conducted resource surveys and evaluations for 7 types of medicinal materials as part of its classic prescription development project[31]. - The company is committed to the innovation and development of traditional Chinese medicine, focusing on both heritage and modern advancements[31]. - The company plans to enhance its research and development capabilities to drive innovation in its product offerings[152]. Environmental Compliance - The company has not faced any administrative penalties related to environmental issues during the reporting period, ensuring compliance with national environmental protection laws and regulations[79]. - The company has implemented a rainwater and sewage diversion project, effectively reducing wastewater generation after investing 900,000 yuan in October 2017[75]. - The company has established an emergency response plan for sudden environmental incidents, focusing on prevention and improving the response mechanism[78]. - The company has conducted environmental self-monitoring according to national standards, with all monitored pollutants meeting or exceeding national discharge standards[79]. Shareholder Information - The total number of shares is 239,471,267, with 99.96% being unrestricted shares[107]. - The number of shareholders at the end of the reporting period is 16,682[109]. - The largest shareholder, Qidi Technology Service Co., Ltd., holds 29.41% of the shares, totaling 70,432,904 shares[109]. - The company has not disclosed any plans for share repurchase or issuance in the current report[107]. Risk Management - The company emphasizes that forward-looking statements do not constitute substantive commitments to investors, urging caution regarding investment risks[3]. - The company is actively monitoring raw material prices and implementing cost management strategies to mitigate risks from price fluctuations[65]. - The company plans to enhance its product line by increasing R&D investment and exploring mergers and acquisitions to mitigate risks associated with a single product structure[64].

Financial Performance - The company's revenue for Q1 2022 was ¥92,417,774.85, representing a 20.43% increase compared to ¥76,738,641.22 in the same period last year[2] - Net profit attributable to shareholders decreased by 38.90% to ¥12,501,913.58 from ¥20,462,099.92 year-on-year[2] - Basic and diluted earnings per share fell by 38.88% to ¥0.0522 from ¥0.0854 in the same period last year[2] - The net profit for Q1 2022 was ¥12,450,763.04, a decrease of 39.1% from ¥20,462,099.92 in the same period last year[18] Cash Flow - The net cash flow from operating activities was negative at -¥38,063,764.03, a decline of 1,101.10% compared to ¥3,802,179.07 in the previous year[2] - Cash flow from operating activities showed a net outflow of ¥38,063,764.03, compared to a net inflow of ¥3,802,179.07 in the previous year[20] - The net cash flow from investing activities was -¥90,046,797.81, an increase of 82.64% compared to -¥49,301,913.95 in the previous year, mainly due to increased purchases of financial products[7] - Cash flow from investing activities resulted in a net outflow of ¥90,046,797.81, worsening from a net outflow of ¥49,301,913.95 in Q1 2021[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥962,747,888.34, a decrease of 0.52% from ¥967,825,750.64 at the end of the previous year[2] - The total liabilities decreased from ¥285,504,415.17 to ¥266,475,789.83, indicating a reduction of approximately 6.7%[14] - Cash and cash equivalents at the end of the period were ¥119,943,241.49, down from ¥250,681,302.32 at the beginning of the year, a decline of 52.2%[12] - The company's inventory decreased from ¥86,592,655.37 to ¥84,374,140.69, a reduction of about 2.5%[12] Shareholder Information - The company has a total of 16,443 common shareholders at the end of the reporting period[9] - The top ten shareholders hold a combined 62.41% of the company's shares, with the largest shareholder owning 29.41%[9] Research and Development - Research and development expenses increased by 46.37% to ¥2,678,282.04, reflecting higher investment in R&D[6] - Research and development expenses increased to ¥2,678,282.04 from ¥1,829,778.17, indicating a focus on innovation[17] Operating Costs - Total operating costs amounted to ¥79,371,107.18, up from ¥60,742,582.21, reflecting a 30.7% increase year-over-year[17] - The company experienced a significant increase in sales expenses, which rose to ¥15,070,557.79 from ¥9,940,230.38, reflecting higher marketing efforts[17] Non-Recurring Gains and Losses - The company reported a total of ¥1,928,696.71 in non-recurring gains and losses for the period[4] Equity - The total equity attributable to the parent company increased from ¥680,322,069.07 to ¥692,823,982.65, reflecting a growth of approximately 1.9%[14]